1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Next-Generation Glycemic Control Therapeutics

Next-Generation Glycemic Control Therapeutics

  • August 2015
  • -
  • Greystone Research Associates

The Promise of New Drug Classes & MOAs

As the number of patients diagnosed with diabetes continues to climb worldwide, drug developers and researchers are attempting for find more effective ways to control glucose levels, particularly for Type 2 diabetics. These efforts have led to a growing list of GLP-1 agonists and DPP-4 inhibitors that have been approved or are in late stage clinical development. New medicines based on novel therapeutic moieties and potentially unique benefits are attracting attention and research investment. The result is an evolving therapeutic landscape that is providing clinicians and patients with new ways to manage their diabetes. For market participants, product positioning and prescriber training will become increasingly important as competitive threats remain fluid.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

What You Will Learn

- What therapeutic drugs are currently marketed for glycemic control, how are they administered, who markets them, and what is the size of the global market?
- What are the important factors in patient self-administration of glycemic drugs, what are the current prescribing trends, and what are the key factors influencing demand?
- What are the regional factors affecting market size and demand?
- What are the new classes of drugs that are entering the market for treating diabetes, what is their market share and what are their growth prospects?
- What drugs are expected to enter the market in the next five years, and what will be their probable impact on the overall market?
- What are the significant economic, technology, and regulatory factors affecting the market for glycemic control therapeutics?

Table Of Contents

Next-Generation Glycemic Control Therapeutics
Executive Summary
The Market Opportunity
Glycemic Control Market Dynamics
Market Segments
What's Driving the Market?
Shifting Demographics
Therapeutic Demand Drivers
Competitive Landscape
Risk Factors
Approved Next-Generation Therapeutics
Inhaled Insulin
GLP-1 Agonists
Amylin Analogs
DPP-4 Inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors
Development-stage Glycemic Control Products
Inhaled Insulin
GLP-1 Agonists
DPP-4 Inhibitors
SGLT2 Inhibitors
Dual Therapy Drugs
New MOAs
Glucagon Receptor Antagonist
Market Data and Forecasts
Market Factors
Regulatory Issues
Patient Compliance and Ease of Use
Healthcare Economics
Regional Market Factors
Company Profiles

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • $ 6 650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories ...

Renal Disease Treatments: Products and Therapies

Renal Disease Treatments: Products and Therapies

  • $ 6 650
  • Industry report
  • June 2016
  • by BCC Research

This BCC Research report provides a comprehensive analysis of the renal disease market and its trends from 2016 through 2021. In-depth analysis is provided on predominant treatment of kidney diseases, ...

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

  • $ 6 995
  • Industry report
  • August 2016
  • by GBI Research

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.